Abstract Library

#4597 FIT-NETs: Assessing the effects of an exercise programme on the physical and emotional well-being of patients with advanced G1-2 NETs of GEP or unknown origin

Introduction: Physical activity programs in solid tumours have shown to improve symptom control and even survival, but their impact on NENs remains unexplored. Advanced disease, systemic therapy, and hormonal secretion in these tumours often lead to muscle wasting and sarcopenia.

Conference:

Presenting Author: Anton-Pascual B

Authors: Anton-Pascual B, Rodriguez-Gomez J, de Cima A, Herrero-Llorente A, Modrego A,

Keywords: FIT-NET, physical exercise program, Quadriceps, MEP & MIP, QoL,

#4399 Updated data from a single-arm, open-label, multicentre clinical study on the efficacy and safety of surufatinib combined with EP regimen and serplulimab in first-line treatment of NEC

Introduction: NEC is an aggressive neuroendocrine neoplasm with limited treatment options. Surufatinib (SUR), a kinase inhibitor targeting VEGFRs, FGFR-1, and CSF-1R, improves vascular normalisation and tumour microenvironment, synergising with chemo- and immunotherapy.

Conference:

Presenting Author: Lin Z

Authors: Zhang T, Lin Z, Zhao L, Ma H, Zhang D,

Keywords: NEC, surufatinib, EP, first-line,

#4392 Updated results of first-line chemotherapy combined with an immune checkpoint inhibitor for advanced extrapulmonary neuroendocrine carcinoma: A single arm, phase II study

Introduction: NEC is a rare, aggressive cancer with limited response to standard first-line chemo (etoposide + cisplatin/carboplatin, EP/EC).

Conference:

Presenting Author:

Authors: Cao D, Li X, Li R, Wang X, Yang Y,

Keywords: neuroendocrine carcinoma, First-line, chemotherapy, camrelizumab,

#4374 Efficacy and safety of immunotherapy combined with antiangiogenesis agents and temozolomide in neuroendocrine carcinoma

Introduction: Platinum-based doublet chemotherapy is the standard first-line treatment, without standard treatment for second-line or subsequent systemic therapy for recurrent or progressive advanced neuroendocrine cancer (NEC).

Conference:

Presenting Author:

Authors: Li X, Yang M, Fan Q, Song L,

Keywords: Neuroendocrine carcinoma, Immunotherapy, Antiangiogenesis agents, Temozolomide,

#4104 Promising outcomes with surufatinib-vinorelbine combination therapy in lung cancer with neuroendocrine differentiation

Introduction: Lung cancer (LC) remains one of the most prevalent and deadly cancers worldwide. Neuroendocrine differentiation (NED) is observed in 25-33% of LC cases. NSCLC patients with NED (NSCLC-NED) often have worse outcomes, resembling SCLC behaviour.

Conference:

Presenting Author:

Authors: Chai M, Zhang Y, Wang Y, Lu Z, Xie J,

Keywords: NSCLC-NED, treatment, surufatinib, vinorelbine,